TY - JOUR
T1 - Haemodynamic effects of intravenous isosorbide-5-mononitrate in acute and chronic left heart failure of ischaemic aetiology
AU - Rabinowitz, B.
AU - Katz, A.
AU - Shotan, A.
AU - Chouraqui, P.
AU - Neufeld, H. N.
PY - 1988/1/1
Y1 - 1988/1/1
N2 - Isosorbide-5-mononitrate was administered in a continuous intravenous infusion, according to the haemodynamic response, to 19 patients with left heart failure of ischaemic aetiology; 12 with acute heart failure complicating an acute myocardial infarction and 7 with chronic ischaemic failure. In both groups, the following statistically significant haemodynamic changes were observed: a decrease in PCWP from 25.4 ± 4.6 to 17.2 ± 4.6 mmHg; an increase in SWI from 19.1 ± 10 to 23.6 ± 13.1 gm m-2; a slight increase in cardiac index with no change in arterial pressure and only minimal decrease in vascular resistance. There were two major differences in the haemodynamic response between the patients with acute heart failure and those with chronic disease: (a) the duration of the effect of isosorbide-5-mononitrate on the PCWP was longer in the first group (mean, 8 hours, compared to 1.5 hours in the chronic group), and (b) the effect on afterload was more pronounced in the group with chronic ischaemic failure than in the first group. Thus, isosorbide-5-mononitrate administered by intravenous infusion under careful monitoring appears to have a beneficial role in the treatment of acute as well as chronic ischaemic heart failure.
AB - Isosorbide-5-mononitrate was administered in a continuous intravenous infusion, according to the haemodynamic response, to 19 patients with left heart failure of ischaemic aetiology; 12 with acute heart failure complicating an acute myocardial infarction and 7 with chronic ischaemic failure. In both groups, the following statistically significant haemodynamic changes were observed: a decrease in PCWP from 25.4 ± 4.6 to 17.2 ± 4.6 mmHg; an increase in SWI from 19.1 ± 10 to 23.6 ± 13.1 gm m-2; a slight increase in cardiac index with no change in arterial pressure and only minimal decrease in vascular resistance. There were two major differences in the haemodynamic response between the patients with acute heart failure and those with chronic disease: (a) the duration of the effect of isosorbide-5-mononitrate on the PCWP was longer in the first group (mean, 8 hours, compared to 1.5 hours in the chronic group), and (b) the effect on afterload was more pronounced in the group with chronic ischaemic failure than in the first group. Thus, isosorbide-5-mononitrate administered by intravenous infusion under careful monitoring appears to have a beneficial role in the treatment of acute as well as chronic ischaemic heart failure.
UR - http://www.scopus.com/inward/record.url?scp=0023908083&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/9.suppl_a.175
DO - 10.1093/eurheartj/9.suppl_a.175
M3 - Article
C2 - 3409914
AN - SCOPUS:0023908083
SN - 0195-668X
VL - 9
SP - 175
EP - 180
JO - European Heart Journal
JF - European Heart Journal
IS - SUPPL. A
ER -